In the ER, there's a moment every physician knows but nobody warns you about.

You've got a full board — five, six patients, all in motion. Labs pending, consults running, admissions stacking up. You're moving fast, making calls, keeping the machine running. And then, one by one, the dispositions come through. Admitted. Discharged. Transferred. The board starts to clear.

And suddenly it's empty.

No patients. No pending results. No active plans. Just a blank whiteboard and the hum of a department waiting for the next ambulance.

That's where Lacy and I are this week.

Last edition, I told you we were waiting on lender results. We got them — and the numbers exceeded anything we expected. Pre-approved for an SBA loan. And we secured a home equity line of credit that gives us a runway for the costs that come before closing — due diligence, legal fees, inspections, and anything else that hits before the SBA funds land.

The financing is locked. We have real buying power now.

But the deals that were on our board? They didn't make it.

———

The pool route — the deal we'd been tracking since Edition 3, the one that got us our first broker response, the one that taught us how proof of funds works and what a seller engagement process looks like — we're not pursuing it.

It wasn't a dramatic failure. There was no red flag moment, no flare gun this time. The financing options for pool routes are limited. SBA lenders prefer the business to be local to the borrower, and running a Las Vegas operation remotely from Utah added a layer of complexity that didn't make sense for a first acquisition. The drug testing franchise ran into similar headwinds — remote operation from out of state made it a harder fit than the numbers alone suggested.

So we made the call. Move on.

Here's what I want to name about that decision, because I think it matters: walking away from a deal you've invested time in doesn't feel like progress. It feels like resetting. You've built momentum, done the research, mapped the process — and now the board is blank again.

But in the ER, a clear board isn't a failure. It means you handled what came in, made the right dispositions, and you're ready for whatever walks through the door next. The difference between a clear board and an empty one is what you've learned between patients.

We learned a lot from the pool route. How brokers vet buyers. What proof of funds actually signals. How SBA lending works — and where it doesn't. That education came from the deal, not the textbook.

The board is clear. We're not starting over. We're starting sharper.

———

The financing milestone is real and worth stating plainly: we are pre-approved for SBA funding, and our HELOC closes this week — a dedicated line for the upfront costs that come before the SBA funds land. When we re-enter the market, the conversation with brokers and sellers is different. We're not asking "can we afford this?" — we're asking "is this the right one?"

The pipeline through BizBuySell has been quiet. No deals cleared our triage filters this week. That tells us we need to widen the aperture — BizScout, alternative platforms, direct outreach, community deal flow. All of it goes active now.

I'm wrapping up Unit 7 today — due diligence. The remaining units will be done in the next week or two. After that, it's all execution.

Lacy and I are also leaning into community meetings — deal sourcing, deal prep, deal critiques with fellow acquirers. The pipeline may be empty, but the network isn't.

———

The focus now is singular: find the right deal. Widen the sourcing. Get in front of more deal flow. Attend every community session that puts us closer to the next case.

I don't know what the next deal looks like yet. I don't know the industry, the geography, or the seller's story. But I know something I didn't know five weeks ago: we can move on a deal when we find one. The financing is there. The process is proven. The system works.

The board is clear. The department is quiet. But the ambulance is always on its way.

———

— Joe & Lacy

Clear board. Full kit. Ready.

Subscribe to Acquisition Rx | Follow on X | LinkedIn